Altimmune, Inc. (ALT) vs Valneva SE Sponsored ADR (VALN)

Altimmune, Inc. and Valneva SE Sponsored ADR are both Biotechnology companies. Altimmune, Inc. and Valneva SE Sponsored ADR are of similar size ($593.3M and $589.8M). Altimmune, Inc. has negative trailing earnings, so its P/E is not meaningful; Valneva SE Sponsored ADR trades at 65.3×. Altimmune, Inc. grew revenue faster over the last twelve months: 130.0% against −53.2%. Altimmune, Inc. has the higher net margin (0.00% vs −12.0%) and the lower return on invested capital (−34.3% vs 0.00%). Across the 17 metrics below, Valneva SE Sponsored ADR leads on 10 and Altimmune, Inc. on 7.

Valuation

Metric ALT VALN Biotechnology median
P/E n/m 65.32 7.88
P/S 12,336.04 3.33 11.47
P/B 1.20 5.80 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 46.45 0.74
EV/Sales 6,007.86 3.78 10.73
Earnings yield (25.49%) 1.53% (28.84%)
Free cash flow yield (13.53%) (10.77%) (23.03%)

Profitability

Metric ALT VALN Biotechnology median
Gross margin 100.00% 38.28% 65.16%
Operating margin 0.00% 13.56% 0.00%
Net margin 0.00% (12.01%) 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (28.87%) 0.00% (57.72%)
Return on assets (25.58%) 0.00% (49.22%)
Return on invested capital (34.30%) 0.00% 0.00%

Growth

Metric ALT VALN Biotechnology median
Revenue growth (TTM) 130.00% (53.16%) 5.64%
EPS growth (last fiscal year) 25.37% (805.88%) —
Revenue growth, 5-year CAGR (65.33%) 9.41% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALT VALN Biotechnology median
Debt to equity 0.07 2.27 0.00
Current ratio 26.78 2.16 4.73
Net debt to EBITDA 2.49 (1.15) 0.96

Dividend

Metric ALT VALN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ALT VALN Biotechnology median
Market cap 593.28m 589.78m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack